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ABSTRACT 
Oncolytic reovirus can be delivered both systemically and intratumorally, in both pre-clinical 
models and in early phase clinical trials.  Reovirus has direct oncolytic activity against a variety 
of tumor types and anti-tumor activity is directly associated with immune activation by virus 
replication in tumors. Immune mechanisms of therapy include both innate immune activation 
against virally infected tumor cells, and the generation of adaptive anti-tumor immune 
responses as a result of in vivo priming against tumor-associated antigens. We tested the 
combination of local oncolytic reovirus therapy with systemic immune checkpoint inhibition. We 
show that treatment of subcutaneous B16 melanomas with a combination of intravenous (i.v.) 
anti-PD-1 antibody and intratumoral (i.t.) reovirus significantly enhanced survival of mice 
compared to i.t. reovirus (p<0.01) or anti-PD-1 therapy alone. In vitro immune analysis 
demonstrated that checkpoint inhibition improved the ability of NK cells to kill reovirus-infected 
tumor cells, reduced Treg activity, and increased the adaptive CD8+ T cell dependent anti-tumor 
T cell response. PD-1 blockade also enhanced the anti-viral immune response but through 
effector mechanisms which overlapped with, but also differed from those affecting the 
antitumor response. Therefore, combination with checkpoint inhibition represents a readily 
translatable next step in the clinical development of reovirus viroimmunotherapy.  
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INTRODUCTION 
Reovirus is a double stranded RNA virus with oncolytic activity in a variety of cancer cell types 
[1]. Although reovirus has been demonstrated to replicate independently of the Ras-EGFR 
pathway in certain cells [2], direct oncolysis can occur as a result of defective anti-viral PKR 
signalling in many tumor cells, leading to efficient viral replication and preferential tumor cell 
lysis. We, and others, have also shown that the anti-tumor efficacy of reovirus depends upon a 
potent anti-tumor immune response through activating dendritic cells (DCs) to stimulate both 
NK cell and T cell mediated cytotoxicity [3-8]. Following on from these pre-clinical studies, 
safety of reovirus serotype 3 Dearing strain (Oncolytics, Reolysin) alone, or in combination with 
other therapies, has been demonstrated in several phase I/II clinical trials [9-16]  
During normal cellular immune homeostasis, several immune checkpoint ligand-receptor 
interactions act as negative regulators of T cell responses to regulate autoimmunity and 
prevent damage to healthy tissues [17]. Programmed cell death-1 (PD-1) is a checkpoint 
receptor expressed on T, B cells, and monocytes [18, 19], binding of which to its ligands PD-
L1, PD-L2 inhibits T cell activation [20, 21]. In this way, expanding T cell responses to, for 
example, viral infections or tumor development, are restricted and dampened. In this respect, it 
is now clear that expression of molecules such as PD-L1 is one of the many mechanisms 
which tumors employ to inhibit developing anti-tumor T cell responses [22-24] and evade 
immune surveillance [25]. As a result, antibodies blocking the interaction of immune checkpoint 
molecules expressed on the surface of tumor cells with their ligands on immune cells, have 
been shown to ameliorate such tumor-induced immune suppression and enhance anti-tumor 
responses [26, 27]. Clinical trials have now shown the efficacy of anti-checkpoint inhibitor 
antibodies for the treatment of cancer patients [28-30] and FDA approval has recently been 
granted for their clinical use.  
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Since oncolytic viruses activate anti-tumor immune effector cells, either innate and/or adaptive 
[31, 32], their use in combination with immune checkpoint inhibitors is attractive to boost 
developing T cell responses against systemic tumor [33-35]. However, checkpoint inhibitors 
used in the context of oncolytic virotherapy will have the added effect of de-suppressing anti-
viral T cell responses, which normally act to restrict viral replication.  Immune responses 
against the virus which prevent further replication are generally regarded as detrimental to the 
efficacy of the directly oncolytic component of the virotherapy [31, 36]. In such instances, de-
suppression by checkpoint inhibition would be predicted to reduce overall therapy.  In contrast, 
antitumor therapy may actually benefit from those immune responses which contribute to 
tumor clearance [7, 37-39], in which case immune checkpoint inhibition may add to, or 
synergise with, direct oncolytic virotherapy in clearing tumor cells.  Finally, any differential 
effects of immune checkpoint inhibitors on both innate, and adaptive, immune effectors, to both 
virus and tumor, will also impact on overall treatment efficacy. Thus, although de-suppression 
of local acting, innate immune responses to virus infection may act to restrict viral oncolysis, it 
may, conversely, increase local immune-mediated tumor clearance.  Similarly, immune 
checkpoint inhibition of slower developing, adaptive antitumor T cell responses would be 
expected to contribute to improved overall therapy, whilst preventing the suppression of anti-
viral T cell responses may lead to decreased efficacy of repeated treatments.  Therefore, the 
overall therapeutic effects of immune checkpoint inhibitor therapy, in combination with oncolytic 
viroimmunotherapy are likely to be dependent upon multiple factors including the nature of the 
virus, the checkpoint inhibitor, the tumor type and pragmatic issues such as the relative timing 
of administration of the agents.  
Therefore, in the current study, we investigated whether it would be possible to combine 
systemic checkpoint inhibitor therapy with local viroimmunotherapy using oncolytic reovirus in 
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our pre-clinical model of subcutaneous (s.c.) B16 melanoma.  We show here that combining 
intravenous (i.v.) anti-PD-1 antibody with intra-tumoral (i.t.) reovirus, significantly enhanced 
survival compared to either therapy alone.  Successful combination therapy was associated 
with an enhanced ability of natural killer (NK) cells to recognize, and kill, reovirus-infected 
target tumor cells, an anti PD-1 antibody-mediated reduction in regulatory T cell (Treg) activity 
in reovirus-treated mice, and an increased adaptive CD8+ antitumor T cell response. Our data 
show that combination with checkpoint inhibition represents a readily translatable next step in 
the clinical development of reovirus viroimmunotherapy.  
RESULTS 
PD-1 blockade with i.t. reovirus prolongs survival. We used a regimen of treatment of s.c. B16 
tumors in C57Bl/6 immune competent mice with i.t. reovirus [5] such that virus delayed tumor 
growth but had no significant effect on survival compared to PBS-treated mice (Fig.1).  In this 
model, systemic treatment with anti-PD-1 antibody also gave no survival benefit (Fig.1).  In 
contrast, when anti-PD-1 antibody was administered starting 7 days after the first i.t. virus 
treatment, combining both treatments significantly prolonged survival of mice (p< 0.001 
compared to i.t. reovirus), and cured ~40% of mice. Cured mice were tumor free for >100 days.   
PD-1 blockade and reovirus together augments the IFN-γ response against melanoma tumor-
associated antigens.  An IFN-γ memory recall response to B16 tumor cell lysates was detected 
from pooled splenocytes and lymph node (splenocytes/LN) cells of mice treated with i.t. 
reovirus, but not from mice treated with i.t. PBS (p=0.035) (Fig.2a), confirming our previous 
reports that oncolytic reovirus effectively primes antitumor T cell responses [4, 8]. Consistent 
with the increased therapy associated with combination with anti-PD-1 treatment (Fig.1), 
splenocytes/LN from mice treated with the combination of reovirus and anti-PD-1 generated 
significantly higher levels of IFN-γ in response to B16 tumor lysates compared to reovirus 
alone (p=0.017) (Fig.2a).  <20ng/ml of IFN-γ were secreted in response to lysates of the 
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prostate (non-melanoma) TC2 cell line, indicating that these T cell responses were tumor 
specific (data not shown and Fig.5).  With respect to the specificity of these anti-B16 
responses induced by i.t. reovirus, splenocytes/LN cells from both reovirus/PBS and 
reovirus/anti-PD-1 groups (mice 4&5; 8&9 of Fig.2a) contained T cells specific for the murine 
(but not human) gp100, TYRP-1 and TYRP-2 melanoma antigens. However, as for the B16 
lysates, addition of anti-PD-1 treatment to i.t. reovirus significantly enhanced the magnitude of 
the anti-melanoma responses (Fig.2b). These data show that addition of PD-1 checkpoint 
inhibition to reovirus therapy augments the in vivo IFN-γ response against melanoma tumor-
associated antigens.  
PD-1 blockade augments reovirus-induced NK cell activation and killing.  We have previously 
shown that both tumor[4, 6-8], and immune[3], cell infection with reovirus elicits NK cell 
mediated innate immune responses.  Therefore, we investigated the impact of anti-PD-1 
treatment on NK cell recognition of reovirus-infected tumor cells. Neither B16 tumor cells, nor 
cultures enriched for purified splenic NK cells, alone produced high levels of tumor necrosis 
factor alpha (TNF-α).  However, co-culture of both together led to a significant increase in TNF-
α production (p<0.0001), which was significantly further enhanced when the B16 cells were 
pre-infected with reovirus (p<0.0001, 2-way ANOVA) (Fig.3a). Addition of anti-PD-1 antibody 
significantly increased TNF-α production by NK-enriched cultures in the presence of reovirus 
pre-infection of B16 targets compared to co-cultures treated with an isotype control (p<0.0001), 
but did not alter NK recognition of uninfected B16 targets (Fig.3a). In vitro PD-L1 blockade had 
a much smaller, although still significant, effect on enhancing NK recognition of reovirus-
infected B16 cells (p<0.0001) (Fig.3a).  
Although co-culture of NK-enriched cultures with reovirus-infected tumor cells did not 
significantly reduce reovirus titers produced by the B16 cells (Fig.3b), addition of anti-PD-1 
antibody to these co-cultures resulted in a significant decrease in reovirus titers (p=0.037) 
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(Fig.3b), presumably reflecting the decreased tumor cell numbers available for reovirus 
replication (Fig.3c).  Neither anti-PD-L1, nor isotype control IgG, decreased reovirus titers 
compared to co-cultures with NK cells alone (Fig.3b).  The addition of anti-PD-1, anti-PD-L1 or 
isotype control antibodies to uninfected B16-NK co-cultures had no effect on tumor cell survival 
(Fig.3c). Consistent with additional virus-mediated killing of B16 cells, addition of reovirus to 
B16/NK co-cultures reduced viable cell numbers (Fig.3c). However, the addition of anti-PD-1 
antibody to reovirus-infected B16 /NK cell co-cultures significantly augmented NK cell-
mediated tumor killing compared to the addition of no antibody (p=0.012), a control IgG or anti-
PD-L1 antibody (Fig.3c).  Although PD-1 expression could be detected at low levels on resting 
CD4 cells, minimal levels of PD-1 were detectable on the resting CD8 T cells and NK cells 
used in these experiments (Fig.3D-F). Therefore, the anti-PD-1-augmented NK activation of 
tumor cell killing by reovirus infection observed in these NK-enriched populations in vitro 
(Fig.3A-C) was most likely occuring through indirect mechanisms.  Consistent with this, the 
NK-enriched cultures contained a signficant number of non-NK cells which expressed high 
levels of PD-1 (Fig.3G).  Taken together, these data suggest a model in which anti-PD-1 
treatment alleviated suppression of NK mediated anti tumor activity exerted by a population of 
PD-1Hi innate immune cells, which secrete factors which directly activate NK cell mediated 
killing of tumor cells in a reovirus sensitive manner.       
Reovirus in combination with NK cells affects the levels of PD-L1 on tumors. The B16 cells 
used in this study expressed high levels of PD-L1 (Fig.4a) but these were not significantly 
changed upon infection by reovirus at the indicated MOI (Fig.4a).  Similarly, co-culture of B16 
cells with NK cells in vitro did not alter the high levels of PD-L1 expressed by the tumor cells 
(Fig.4b).  Pre-infection of the tumor cells with reovirus, followed by co-culture with NK cells, led 
to a small increase in PD-L1 levels on the B16 cells (Fig.4b).  PD-L1 levels on NK cells were 
not altered by reovirus infection of B16 cells prior to co-culture (Fig.4c). Taken together, these 
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data suggest that the therapeutic effects of anti-PD-1 in vivo were not due to direct effects on 
PD-L1 expression as a result of tumor cell infection by reovirus but mediated by NK cells via 
enhanced recognition of reovirus infected tumor cells.  
PD-1 blockade ameliorates Treg suppression.  As before, splenocyte/LN cells from mice treated 
with reovirus/anti-PD-1 (Fig.2a) had stronger memory recall responses against B16 tumor cell 
lysates than did splenocytes/LN cells from mice treated with reovirus/PBS (Fig.2a and Fig.5a).  
Depletion of CD8+ T cells from these splenocyte/LN cultures almost completely eradicated 
IFN-γ production in response to B16 tumor lysates, irrespective of the treatment group 
(Fig.5a).  Conversely, Treg depletion from the splenocyte/LN cultures of mice treated with i.t. 
reovirus alone significantly augmented IFN-γ production in response to re-stimulation with B16 
lysates (Fig.5a).  However, Treg depletion from the splenocyte/LN cultures from mice treated 
with i.t reovirus and i.v. anti-PD-1 did not alter the already increased levels of IFN-γ production 
in response to B16 tumor lysates (Fig.5a).  These data suggest that a CD8+ Th1 antitumor T 
cell response induced by i.t. reovirus treatment is suppressed by Treg and that in vivo treatment 
with anti-PD-1 antibody acts to abrogate Treg activity.  
Differential mechanisms of checkpoint inhibition of antitumor and antiviral responses.  
Splenocyte/LN cells from treated mice did not have detectable (<20ng/ml IFN-γ) recall 
responses to the prostate cancer TC2, non-melanoma cell line, indicating that the Th1 
response induced by i.t. reovirus (Figs.2&5a) was tumor specific (data not shown).   Therefore, 
to assess the effects of anti-PD-1 therapy on the antiviral response, the recall response to 
reovirus-infected TC2 cells was measured. Anti-reo IFN-γ production from splenocyte/LN cells 
from reovirus/anti-PD-1 treated mice was significantly augmented compared to mice treated 
with i.t. reovirus alone (p=0.031) (Fig.5b).  As for the antitumor response, the anti-reovirus T 
cell response was significantly (p< 0.0001) reduced upon depletion of CD8+ T cells from the 
splenocyte/LN cultures irrespective of the treatment (Fig.5c). However, unlike the antitumor 
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response (Fig.5a), depletion of CD8+ T cells from splenocyte/LN cultures did not completely 
eradicate IFN-γ production in response to reovirus, suggesting that the anti-reovirus response 
was also contributed by a non-CD8+ T cell component (Fig.5c). Also in contrast to the 
antitumor Th1 response (re-stimulation with B16 lysates, Fig.5a), depletion of Treg did 
significantly enhance IFN-γ production from splenocyte/LN cultures of mice treated with i.t. 
reovirus and anti-PD-1 (p< 0.0001) (Fig.5c).  Measurement of tumor infiltrating immune 
subsets from tumors of mice treated with reovirus alone, or reovirus with anti-PD-1, at a single 
time point, (day 22 after tumor challenge, 3 i.t. reo and 4 doses of i.v. anti-PD1 or isotype 
antibody), did not reveal any significant differences in the levels of tumor infiltrating CD4, CD8, 
NK, or Treg cells between groups (Fig.5D).  Experiments are underway to investigate whether 
this lack of difference reflects the fact that anti-PD-1 treatment affects qualitative, rather than 
quantitative, aspects of tumor infiltrating cell types or whether significant changes occur at 
different time points in the treatment schedule.   
Both innate and adaptive immunity contribute to the in vivo efficacy of reovirus with PD-1 
blockade.  Our in vitro studies suggested that the improved therapy conferred by i.v. anti-PD-1 
antibody (Fig.1) was mediated through effects on both NK cells (Fig.3) and CD8+ T cells, 
(Fig.5).  Consistent with these data, depletion of either NK (P= 0.0004), or CD8+ T (p=0.0024), 
cells significantly reduced the antitumor efficacy of i.t. reovirus with i.v. anti-PD-1 therapy 
compared to non-depleted mice (Fig.6). However, depletion of CD4+ T cells had no significant 
effect on antitumor therapy (Fig.6).  
DISCUSSION 
We show here, for the first time to our knowledge, that reovirus oncolytic viroimmunotherapy 
can be successfully combined with immune checkpoint inhibitor therapy.  Our data 
complement previous reports in which other oncolytic viruses have been used in tandem with 
immune checkpoint inhibitors [33-35].  Cumulatively, these data sets confirm that oncolytic 
A
cc
ep
ed
 m
an
us
cr
ip
t
ACCEPTED ARTICLE PREVIEW 
© 2015 The American Society of Gene & Cell Therapy. All rights reserved 
virotherapy can be regarded as a form of immunotherapy and that strategies aimed at 
enhancing the immune based component of this approach are likely to enhance its therapeutic 
efficacy  [5-7].  
Consistent with our previous studies on reovirus oncolysis in the B16 model [4, 6-8, 40] i.t. 
injection of established tumors primed tumor-specific Th1 T cell responses against both tumor 
cells (Fig.2a), and against defined melanoma-associated antigens (Fig.2b).  These results 
indicated that both direct oncolysis, as well as the immune based activation that accompanies 
it [4, 6, 8, 40], provides sufficient immune activation to break tolerance to self -antigens 
expressed by the tumor (Fig.2b). Therefore, we hypothesized that the immune stimulating, T 
cell priming activity associated with direct oncolysis by reovirus could be effectively combined 
with immune checkpoint inhibition.  In this way, the weak antitumor T cell responses generated 
by the immunostimulatory activity of the virus would be enhanced by blockade of negative 
regulatory signals to the activated self-responsive T cells.  Consistent with this hypothesis, 
direct i.t. injection of reovirus, followed 7 days later by multiple systemic administrations of anti-
PD-1 antibody, significantly improved on the therapy associated with either virus, or anti-PD-1 
antibody, alone (Fig.1). 
We initially showed a significant increase in the IFN-γ response to B16 tumor in 
splenocytes/lymph node cells from mice treated with reovirus and anti-PD-1 compared to 
reovirus alone (Fig.2). To dissect the cellular basis of this response in more detail, we 
proceeded to show that the response is mediated by NK cells (Figs.3&6), Treg (Fig.5) and 
CD8+ T cells (Figs.5&6) but not significantly by CD4+ T cells (Fig.6).  The majority of data 
suggests that immune checkpoint inhibitor therapy acts through modulating activation of T 
lymphocytes [29, 30, 41, 42]. However, based on our previous studies showing NK-mediated 
recognition of reovirus-infected tumor cells [3, 4], we investigated the effects of anti-PD-1 on 
NK cell activation in the context of reovirus oncolysis.  As we have reported previously, NK 
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cells were activated by B16 cells in vitro, but this was significantly enhanced by reovirus 
infection (Fig.3a).  In the presence of anti-PD-1 antibody, NK cell activation by reovirus 
infection was significantly enhanced as evidenced by TNF-α secretion (Fig.3a) and target cell 
killing (Fig.3c).  Interestingly, at least in the context of this in vitro assay, anti-PD-1 antibody 
decreased the viral titers associated with NK/B16-reovirus infection (Fig.3b), suggesting that 
the increased immune based killing associated with NK/anti-PD-1 recognition of reovirus-
infected tumor cells may be more important than direct oncolysis effects. Taken together with 
the in vivo confirmation of a strict dependence upon NK cells for reovirus/anti-PD-1 therapy 
(Fig.6), overall our data show that NK activation by, and killing of, B16 tumor cells is 
significantly enhanced by blockade of PD-1.  However, we were unable to detect PD-1 
expression on NK cells from splenocytes/lymph node cells from C57Bl/6 mice (Fig.3), although 
these cells had high levels of PD-L1 (Fig.4).  Therefore, it seems probable that the NK-
dependence of the in vitro (Fig.3) and in vivo (Fig.6) effects of anti-PD-1 treatment with 
reovirus infection were mediated through an indirect mechanism of NK activation. We are 
currently testing the hypothesis that reovirus infection of tumor (PD-1-ve, PD-L1Hi), and/or 
innate immune effectors (PD-1Hi), leads to the secretion of cytokines which directly activate NK 
cell mediated killing of tumor cells.  In this model, anti-PD-1 treatment would alleviate 
suppression of NK-activating cytokine secretion from PD-1Hi innate immune cells  - which is 
exerted through PD-L1 expression by the B16 tumor, NK or other cell types – and which is 
enhanced by reovirus infection. This model is consistent with our previous demonstration that 
reovirus infection of innate immune cells, such as dendritic cells, induces cytokines which 
activate NK killing of tumor [3].  It is also consistent with the results of Fig.3 which show that 
NK cells both recognise (through TNF-α secretion, Fig.3A), and kill (Fig.3C), B16 target cells, 
even in the absence of reovirus infection.  Hence, enhanced activation of NK cells through 
indirect mechansims (such as infection/activation of DC by reovirus) would further add to tumor 
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cell clearance in vivo. In this respect, it is interesting that blockade of PD-L1 was less effective 
at activating NK cell recognition/killing of reovirus-infected B16 cells than blockade of PD-1 
(Fig.3).  This may be due to technical reasons related to the anti-PD-L1 antibody used in our 
studies here, to the fact that other ligands for PD-1 may be recognized in the context of PD-1Hi 
immune cells which mediate NK tumor cell killing, or that PD-1 signaling on innate immune 
effector cells may transmit suppressive signals even in the absence of PD-L1 ligation. 
Therefore, taken together, the in vivo mechanisms by which i.t. reovirus leads to anti-PD-1 
augmented therapy are likely to be pleiotropic, involving both innate and adaptive immune 
effector mechanisms (Figs. 2,3,5&6).   
Reovirus infection alone did not significantly alter the levels of PD-L1 on B16 tumor cells 
(Fig.4a), but addition of NK cells to reovirus infected B16 cells increased PD-L1 on the tumor 
cells (Fig 4b).  Therefore, our in vitro data suggest that the therapeutic effects of i.t. reovirus 
with systemic anti-PD-1 antibody treatment in vivo probably did not derive from direct effects 
on levels of expression of PD-L1, or PD-1, induced by reovirus infection of the tumor cells.  
Therefore, we hypothesise that the in vivo therapy derived from the immune mediated 
sequelae of reovirus infection of tumors – namely tumor cell killing, antigen release, cytokine 
secretion, enhanced recognition via NK cells, and T cell priming.  In this scenario, anti PD-1 
antibody would act upon immune effector cells activated by this immune priming to de-
suppress the developing antitumor response as seen in Figs.1&6.  Experiments are currently 
underway to dissect the immune cell targets for anti-PD-1 activity in vivo (such as CD8+ T 
cells, NK cells, Treg) using knockouts, immune cell depletions and flow cytometry.    
In vitro cultures of splenocytes/LN cells from treated mice showed that the anti-PD-1-mediated 
enhancement of T cell responses against melanoma-associated antigens (Fig.2) was almost 
entirely dependent upon CD8+ T cells (Fig.5a), a result that was also confirmed in vivo (Fig.6).  
As predicted, in vivo blockade of PD-1 also significantly enhanced the Th1 anti-reovirus T cell 
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response (Fig.5b).  However, Fig.5c shows that additional immune effectors contributed to the 
virus specific Th1 response, since in vitro depletion of CD8+ T cells did not completely abolish 
anti-reovirus IFN-γ secretion. It seems likely that NK cell mediated IFN-γ secretion may 
contribute, in part at least, to the anti-reovirus responses seen in these splenocyte/LN cultures 
given the role of NK cells shown in Fig.3. 
Just as depletion of CD8+ T cells abolished the antitumor Th1 response induced by i.t. reovirus 
alone (Fig.5a), so in vitro depletion of Treg dramatically increased it (Fig.5a).  These in vitro 
data correlate closely with our previous in vivo data, which showed that i.t. reovirus is 
associated with induction of a strong Treg response, which can be suppressed by antibody-
mediated depletion of Treg, or by treatment with cyclophosphamide [5]. Interestingly, the in vitro 
antitumor Th1 response was not further enhanced by depletion of Treg from splenocyte/LN cell 
cultures from mice treated with i.t. reovirus and anti-PD-1 - suggesting that  in vivo blockade of 
PD-1 closely mimicked an abrogation of Treg activity.  Although outside of the scope of the 
present study, we are currently investigating whether, and how, blockade of PD-1 affects Treg 
numbers, activity or both.  
In contrast to the results with the antitumor Th1 response, the anti-reovirus Th1 response was 
only moderately increased by in vitro depletion of Treg (Fig.5c). Moreover, the anti-PD-1-
mediated enhancement of the antivirus Th1 response (Fig.5b) was further enhanced by in vitro 
depletion of Treg (Fig.5c).  These data suggest that blockade of PD-1 does not completely 
mimic Treg depletion/abrogation in the context of the antivirus (Fig.5c), as opposed to the 
antitumor (Fig.5a), response.  Taken together, our data show that PD-1 blockade enhanced 
both tumor-specific, and viral-specific, immune responses, but may be acting through different 
immune effectors including CD8+ T cells, NK cells and Treg. 
Overall, our in vivo data show that tumor clearance by the combination of local oncolysis and 
systemic immune checkpoint inhibition absolutely depended upon immune effectors (NK, 
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CD8+ T cells, Fig.6) and that the regimen tested here led to significant synergy between the 
two therapies. However, the use of immune checkpoint inhibitors in the context of oncolytic 
virotherapy poses several possibly conflicting questions regarding its predicted therapeutic 
efficacy. Thus, whilst de-repressing an antitumor, adaptive T cell immune response is likely to 
be beneficial to tumor clearance, de-suppressing antiviral responses (innate or adaptive), 
which normally act to restrict viral spread, may limit further replication which could be 
detrimental to the efficacy of the directly oncolytic component of the virotherapy [31, 36]. 
Conversely, antitumor therapy may benefit from augmenting immune responses, even against 
the virus, which contribute to tumor clearance [7, 32, 37, 39]. Therefore, it is clear that the 
differential effects of immune checkpoint inhibitors on both innate, and adaptive, immune 
effectors, to both virus and tumor, need to be understood to allow for optimal utilization of 
these agents in combination with oncolytic virotherapy. Our data here clearly show that the 
effectors and mechanisms of the antitumor, and antiviral, Th1 responses both share some 
components but also differ in some significant respects. Therefore, it will be important to 
optimize several factors, which may play both complementary, and/or opposing, roles in the 
success of this combination therapy.  In particular, the relative timing of virus and checkpoint 
inhibition may be crucial.  Here, we started anti-PD-1 blockade 7 days after the first virus 
administration.  The rationale of this was to minimize augmenting the anti viral response whilst 
virus injections were still being performed, thereby maximizing the ability of the virus to spread 
within the tumor.  In the regimen of Fig.1, the last reovirus injection was only 2 days before the 
first systemic treatment with anti-PD-1.  Therefore, we believe that appreciable levels of intra-
tumoral reovirus would likely still be present to activate NK cell mediated tumor killing, through 
mechanisms which would be augmented by anti-PD-1 as shown in Fig.3.    In addition, this 
timing was designed to prevent T cell inactivation as the antitumor immune response was 
developing (5-7 days after the initial T cell priming activity of i.t. virus injection (Fig.2b).  
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Therefore, the overall therapeutic effects of immune checkpoint inhibitor therapy, in 
combination with oncolytic viroimmunotherapy, are likely to be dependent upon multiple factors 
including the nature of the virus, the particular checkpoint inhibitor, the tumor type and 
pragmatic issues such as the relative timing of administration of the agents.  
In summary, we show here that oncolytic reovirus therapy can be effectively combined with 
immune checkpoint inhibitor therapy.  Blockade of PD-1 significantly enhanced the CD8+ T cell  
Th1 antitumor response primed by intratumoral reovirus injection and also enhanced NK cell 
recognition of reovirus infected tumor cells.  Treatment with anti-PD-1 mimicked abrogation of 
Treg suppression of the antitumor T cell response. PD-1 blockade also enhanced the antivirus 
Th1 response but not through exactly the same effector mechanisms as for the antitumor 
response.  Therefore, combination with checkpoint inhibition represents a readily translatable 
next step in the clinical development of reovirus viroimmunotherapy, and careful dissection of 
the immune mechanisms operating in both antitumor and antiviral immune responses will help 
to optimize its use.  
Materials and Methods 
Cell lines. Murine B16 cells (American Type Culture Collection, Manassas, Va.) were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Life Technologies, Carlsbad,CA) supplemented 
with 10% (v/v) fetal calf serum (FCS; Life Technologies) and L-glutamine (Life Technologies, 
Carlsbad, CA).  
Reovirus.  Reovirus Type 3 Dearing strain was provided by Oncolytics Biotech, Inc., and 
stored in the dark at neat concentrations in PBS at 4°C (maximum 3 months) or at −80°C 
(long-term storage). Stock titers were determined by standard plaque assays on L929 cells.  
In vivo studies. All procedures were approved by the Mayo Foundation Institutional Animal 
Care and Use Committee. C57BL/6 mice (Thy 1.2+) were purchased from The Jackson 
Laboratory (Bar Harbor, ME) at 6-8 weeks of age. To establish subcutaneous (SC) tumors, 
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5x105 B16-tk tumor cells in 100µl of PBS were injected into the flanks of C57BL/6 mice (7-8 
mice per treatment group unless stated otherwise). Seven days later, mice were treated intra-
tumorally (i.t) with PBS, or reovirus at 7x108/50µl with one dose per day on alternate days, for 
a total of three separate doses. This was followed by intravenous (i.v.) treatments with anti-PD-
1 antibody (BioXcell, West Lebanon, NH) or isotype control antibody (0.25mg/mouse) at times 
as described in each experiment. Tumor sizes were measured three times weekly using 
calipers and were euthanized when tumor size was approximately 1 cm in two perpendicular 
directions.  For in vivo flow cytometry experiments, mice with established tumors were treated 
with 3 doses of reovirus at 7x108/50µl. After four doses of IV treatment with anti-PD-1 antibody 
or isotype antibody, tumors were harvested, stained for immune markers and analyzed by flow 
cytometry (see below).  
In vitro splenic re-stimulation of splenocytes/lymph nodes and enzyme-linked 
immunosorbent assay (ELISA) for IFN-γ/TNF-α. Spleen and lymph nodes (S/LN) were 
immediately excised from euthanized mice and dissociated in vitro to achieve single-cell 
suspensions. Red blood cells were lysed with ACK lysis buffer for 2 minutes as described 
above. Cells were re-suspended at 1x106 cells/mL in Iscove’s Modified Dulbecco’s Medium 
(IMDM; Gibco, Grand Island, NY) + 5% FBS + 1% Pen-Strep + 40 µM 2-ME.  Supernatants 
were harvested from 1x106 LN/S previously stimulated with virus stocks as described in the 
text, with synthetic H-2Kb–restricted peptides murine TRP-2180-188 SVYDFFVWL, murine TRP-
1222-229 TAYRYHLL, human gp10025–33 (hgp100), KVPRNQDWL, and murine gp100 (mgp100) 
EGSRNQDWL and/or with freeze thaw lysates from tumor cells alone or tumor cells infected 
with reovirus in triplicate, every 24h for 3 days. Cell-free supernatants were collected 48 hours 
later and tested by ELISA for murine IFN-γ (BD Biosciences, San Jose, CA) or murine TNF-α 
(BD Biosciences, San Jose, CA). The peptides were synthesized at Mayo Foundation Core 
Facility (Rochester, MN).  
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In vitro cytokine secretion, cell killing and viral titer determination. 104 B16tk cells were 
seeded in media containing anti-PD-1 antibody (100 ng/ml) or anti-PD-L1 antibody (Biox Cell, 
West Lebanon, NH) or isotype-control (Chrome Pure anti-Rabbit IgG, Jackson Laboratories, 
Farmington, CT) and infected with reovirus at MOI 0.1. Forty eight hours post-infection, cells 
were co-incubated with isolated whole S/LN or S/LN enriched with NK cells (see below) 
derived from tumor-naïve C57BL/6 mice (E:T: 10:1). Forty eight or 72 hours post-incubation, 
supernatants were harvested and analyzed for cytokine secretion using ELISA and  viral titers 
were determined by standard plaque assays on L929 cells. The number of viable cells were 
counted using trypan blue staining respectively.  
Flow cytometry. For in vivo analysis of resting immune cells, spleens were harvested from 
C57Bl/6 mice. Splenocytes were stained with CD3-FITC, CD4-Percp, CD8- PE (eBioscience, 
San Diego, CA), PD1-Pe/Cy7 and PD-L1-APC (Biolegend,San Diego, CA) or for CD3-FITC, 
NK1.1-PE (eBioscience San Diego,CA) and PD1-Pe/Cy7, PD-L1-APC. Enriched NK cells 
obtained from in vitro cell fractionation (see below) were stained with CD3-FITC, NK1.1-PE, 
PD1-Pe/Cy7, PD-L1-APC to determine enrichment for NK cells from CD3+ cells. 
For Fig.4, B16 cells were infected with reovirus at MOI= 0.1. Forty-eight hours postinfection, 
cells were co-incubated with NK cells isolated using Miltenyl Kit (as described above) in the 
absence or presence of anti-PD-1 antibody. Forty-eight post incubation, the supernatants were 
harvested, spin at 1200 rpm for 4 minutes. The pelleted cells were stained with CD3-FITC, 
CD45-PerCP (both from BD Bioscience San Diego,CA), NK1.1-PE (eBioscience San 
Diego,CA) and PD-L1-APC (Biolegend, San Diego, CA). Similarly, the tumor cells were also 
stained for CD45-PerCP (BD Bioscience San Diego,CA) and PD-L1-APC (Biolegend, San 
Diego,CA) expression. To determine tumor infiltrating immune cells, tumors from mice were 
stained with CD45-PerCP, CD8-PE. All cells were stained with antibodies with appropriate 
A
cc
ep
te
d 
m
an
us
cr
ip
t
ACCEPTED ARTICLE PREVIEW 
© 2015 The American Society of Gene & Cell Therapy. All rights reserved 
isotype controls for 30 minutes and fixed using 4% paraformaldehyde. For Tregs staining, cells 
were stained extracellularly with CD45-Percp, CD4-FITC, CD25-Pe/Cy7, then fixed and 
permeabilized for intracellular staining for Foxp3-PE (eBioscience San Diego,CA) using the 
mouse T regulatory staining kit from eBioscience according to the manufacturer’s instructions. 
Flow cytometry analysis was carried out by Mayo Microscopy and Cell Analysis core and data 
were analyzed using FlowJo software.  
In vitro cell fractionation. NK cells were purified/depleted from Splenocytes/LN of C57Bl/6 
naïve mice using magnetic sorting with the NK Cell Isolation Kit II microbeads (Miltenyi Biotec, 
Auburn, CA).  CD8+ T cells were isolated using the MACS CD8a (Ly-2) microbead magnetic 
cell sorting system (Miltenyi Biotec, Auburn, CA) as per the manufacturer’s instructions. Treg 
cells were isolated from the combined spleens and lymph nodes of treated mice using the 
CD4+CD25+ Isolation Kit II microbeads (Miltenyi Biotec, Auburn, CA).  The remaining cells (i.e. 
non-Treg) were harvested from in a two step procedure.  Magnetically labeled non-CD4+ T 
cells were eluted from a column following the negative selection of CD25-PE labeled CD4+ T 
cells; subsequently, CD25+ PE-labeled cells in the enriched CD4+ T cell fraction were retained 
on a column, whilst the unlabeled, non–Treg cells were collected. Non-CD4+ (step1), non-
CD25-PE-labeled Treg (step 2) cells were pooled and used in the assays of Figure 5.  
In vivo depletion studies. Immune cell depletions were done by i.v. injections (0.1 mg/mouse) 
of anti-CD8 (Lyt 2.43, BioXcell, West Lebanon, NH) and anti-CD4 (GK1.5 BioXcell, West 
Lebanon, NH) antibodies; anti–natural killer (NK) cells (anti–asialo-GM-1; Cedarlane, Ontario, 
Canada) and IgG control (ChromPure Rat IgG; Jackson ImmunoResearch, West Grove, PA) at 
day 7, 10, 12 after tumor implantation and then weekly thereafter. 
Statistics. Survival data from the animal studies were analyzed by the log-rank test using 
GraphPad Prism 5 (GraphPad Software, La Jolla, CA). Two-sample, unequal variance 
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Student’s t-test analysis was applied for in vitro data. Statistical significance was determined at 
the level of p < 0.05. 
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FIGURE LEGENDS 
Figure 1. Combination therapy of Reovirus with anti-PD-1 antibody. A. C57BL/6 mice 
bearing 7 days established s.c. B16 tumors were treated with three doses of i.t. reovirus (7x108 
pfu/50µl) or with PBS (days 7,10,12).  Starting on day 14, mice were treated i.v. with anti-PD-1 
antibody (0.25 mg/mouse), or with isotype control IgG (ctl IgG), every other day for 8 injections. 
Survival of tumor-bearing C57BL/6 mice (n=7 mice per group) is shown. Data are 
representative of two separate experiments. * p = 0.0084, **P = 0.0005 
Figure 2. PD-1 blockade enhances i.t. reovirus induced Th1 memory T cell responses.  
A. Splenocytes/LN cells from individual C57BL/6 mice bearing s.c. B16 tumors, and treated 
with a combination of i.t. PBS or reovirus and i.v. isotype control antibody (control IgG) or anti-
PD-1 antibody as labeled, were re-stimulated in vitro  with freeze-thaw (F/T) lysates of B16 
tumor cells (equivalent of 106 cells per stimulation). 48hrs later supernatants were assayed for 
secretion of IFN-Ǵ by ELISA. The numbers on the x-axis indicate the mouse number in each 
treatment group. Error bars represent the standard deviation of measurements from triplicate 
wells per sample. B. Splenocytes/LN from C57BL/6 mice bearing s.c. B16 tumors, and treated 
with a combination of i.t. reovirus with i.v. control isotype IgG (black bars) or with anti-PD-1 
(hatched bars) were re-stimulated in vitro with B16 F/T lysates, or with peptides for specific 
melanoma antigens as shown. 48hrs later, supernatants were assayed for IFN-γ by ELISA.  
Each bar represents splenocytes/LN from an individual mouse and measurements were made 
from two mice treated with (i.t. reovirus and i.v. control IgG), or two mice treated with (i.t. 
reovirus and i.v. anti-PD-1).   
Figure 3.  PD-1 blockade augments reovirus-induced NK cell activation and killing.  B16 
cells were mock infected, or infected with reovirus at MOI= 0.1 in the presence of anti-PD-1, 
anti-PD-L1, or isotype control antibody (ctl IgG) at 100 ng/ml. Forty-eight hours later, cells were 
incubated with splenic NK cells isolated from tumor naïve mice at E:T 10:1. 4 days post 
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infection, supernatants were assayed for A. TNF-α secretion by ELISA *** p<0.0001 or B. for 
reovirus titers using plaque assays. C. 7 days -post-infection surviving cells were counted.  D-
F.Splenocytes from C57Bl/6 mice were stained with CD3-FITC, NK-Pe/Cy7 CD4-Percp, CD8-
PE, PD-1-PE/Cy7 fixed and analyzed by flow cytometry. Expression of PD-1 on NK cells (D), 
CD4 T cells (E) and CD8 T cells (F) is shown. G. Splenic NK cells isolated from tumor naïve 
mice were stained with CD3-FITC, NK-PE and PD-1 PE/Cy7. Percentages of CD3+ and NK+ 
cells is shown (left panel). CD3+ cells were further analyzed for PD-1 expression (right panel).   
Figure 4. NK recognition of reovirus-infected B16 cells up-regulates PD-L1 expression 
A. B16 tumor cells were mock (red curve) or reovirus infected at MOI-0.1 (blue curve). After 
four days, the cells were trypsinized, harvested, stained with antibodies against CD45-PerCP, 
PD-L1-APC, fixed and analyzed by flow cytometry.  PD-L1 expression is shown. B&C. Co-
culture incubation. B16 tumor cells were mock (red curve) or reovirus infected at MOI-0.1 (blue 
curve). Forty-eight hours post-infection, NK cells were added at E:T 10:1. Co-cultures, and B16 
without NK cells (orange curve), were then incubated for a further forty-eight hours.  
Supernatants were collected and centrifuged to isolate NK cells, and tumor cells were 
trypsinized and harvested.  Tumor cells were stained with antibodies against CD45-PerCP, 
PD-L1-APC, fixed and analyzed by flow cytometry; PD-L1 expression is shown (panel B). NK 
cells were stained with antibodies against CD3-FITC, NK1.1-PE, PD-L1-APC, fixed and 
analyzed using flow cytometry; PD-L1 expression is shown (panel C).  
Figure 5. PD-1 blockade ablates tumor-specific immune suppression by Treg.  A. C57BL/6 
mice bearing s.c. B16 tumors were treated with i.t. reovirus, in combination with i.v. anti-PD-1 
or isotype (control) IgG (2 mice per group). Non-depleted splenocytes/LN cells (black bars), or 
splenocytes/LN depleted for CD8+ T cells (white bars) or Treg (hatched bars) were stimulated in 
vitro with A. F/T lysates of B16. Forty-eight later supernatants were assayed for IFN-Ǵ by 
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ELISA. Values represent levels each done in triplicate wells (mean ± standard deviation). B. 
Splenocytes/LN from C57BL/6 mice treated with i.t. reovirus, in combination with i.v. anti-PD-1, 
isotype (control) IgG, or PBS (4 mice per group) were stimulated with F/T lysates of reovirus-
infected TC2 cells.  48hrs later, supernatants were assayed for IFN-Ǵ by ELISA. Values 
represent secretion levels for three or four different mice per group, each done in triplicate 
wells (means ± standard deviation). C. C57BL/6 mice bearing s.c. B16 tumors were treated 
with i.t. PBS or reovirus, in combination with i.v. anti-PD-1 or isotype (control) IgG. Non-
depleted splenocytes/LN cells (black bars), or splenocytes/LN depleted for CD8+ T cells (white 
bars)  or Treg (hatched bars) were stimulated in vitro with F/T lysates of reovirus-infected TC2 
cells, * (p< 0.0001).  D. C57BL/6 mice bearing s.c. B16 tumors were treated with i.t. PBS or 
reovirus, with four doses of i.v. anti-PD-1 or isotype (control) IgG. On day 22 after tumor 
implant, tumors were harvested and stained for CD45-PerCP, CD4-FITC, CD25-Pe/Cy7 
followed by intracellular staining with Foxp3-PE or with CD45-PerCP, CD8-PE. The 
percentages of tumor-infiltrating CD3+ T cells which are Tregs (left panel) or CD8+ T cells (right 
panel) are shown. Six tumors were analyzed from each treatment group with mean and 
standard deviation shown. 
Figure 6. Combination therapy of reovirus and anti-PD-1 antibody is dependent upon NK 
cells and CD8+ T cells.  A. 7 days post s.c. B16 tumor challenge, reovirus or PBS were 
administered i.t. along with i.v. injections of depleting antibodies against CD8+ T cells, CD4+ T 
cells or NK cells at days 7,10 and 12 and weekly thereafter. At days 14,17,19,26,28,30,32, and 
33 anti-PD-1 or PBS were administered via i.v injections. Survival of tumor-bearing C57BL/6 
mice (n=7 mice per group) is shown. * p = 0.0024, **p= 0.0004 
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